Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis

This is a solid mid-stage design: randomized, double-blind, placebo-controlled, with three active dose arms, so bias control is good and the sponsor has multiple shots at finding an active dose. But the primary endpoint is demanding. Week 12 clinical remission by modified Mayo Score with an endoscopic requirement is clinically meaningful and objective enough to matter, yet it is a tough hurdle in moderate-to-severe ulcerative colitis, where placebo-adjusted remission signals can be inconsistent. The dose-finding setup also adds risk because participants are split across three SAR443122 doses versus placebo, which can dilute per-arm power unless total enrollment is large; the trial facts do not show a clearly validated dose or prior efficacy signal. The long maintenance period and open-label rollover help characterize durability and rescue nonresponders, but they do not materially de-risk the induction readout that will drive a positive result. Sanofi lowers operational risk, yet biology, dose selection, and endpoint strictness still leave the study below even odds.

Sanofi deprioritized eclitasertib for UC in its January 29, 2026 full-year 2025 earnings disclosure, effectively ending the last RIPK1 program from the Denali collaboration. This deprioritization came right around the trial's primary completion date (Feb 2026), strongly implying Sanofi had access to negative or underwhelming induction data. The RIPK1 inhibitor class has a dismal clinical track record: eclitasertib itself failed in cutaneous lupus (missed CLASI-A primary endpoint) and COVID-19 (missed CRP endpoint). The related CNS-penetrant RIPK1 inhibitor oditrasertib failed in both ALS and MS Phase 2 trials. Multiple other pharma companies (GSK, BMS, Eli Lilly) have abandoned RIPK1 programs. The novel mechanism lacks clinical proof-of-concept in any inflammatory indication. Combined with the typical ~35% base rate for Phase 2 trials in UC hitting clinical remission endpoints, and the decisive signal from Sanofi's portfolio review, positive results are highly unlikely.

This is a Phase 2 dose-finding study for SAR443122 in moderate-to-severe ulcerative colitis. The study uses a modified Mayo score endpoint at Week 12, which is a validated and standard clinical endpoint for UC trials. The design includes 4 parallel arms (3 dose levels vs placebo), allowing for dose-response assessment. Phase 2 studies typically have a success rate around 40-50% for GI indications, and dose-finding studies carry additional uncertainty since the optimal dose hasn't been established. Sanofi has development experience, but this is an early-stage program in a competitive UC landscape with multiple approved therapies. The primary endpoint is clinically meaningful (clinical remission), but the 12-week induction period is relatively short. Given the Phase 2 nature, dose-ranging design, and standard but not novel endpoint, intrinsic probability is estimated at 50% — neither strongly positive nor negative based on available trial facts.

This is a Phase 2 dose-finding study by Sanofi, a major sponsor, for ulcerative colitis. The primary endpoint is clinical remission at Week 12 using the modified Mayo Score, a standard and clinically meaningful measure. The trial design is robust: randomized, double-blind, placebo-controlled, with three active dose arms. The study includes a 52-week treatment period with an induction and maintenance phase, and a rollover option for non-responders, which may aid retention. The primary completion date has passed (-50 days), suggesting top-line data is likely imminent, reducing operational risk. However, it is a dose-ranging study, so the primary goal is signal detection for dose selection, not definitive proof of efficacy. Prior data for the asset is not provided. The intrinsic odds slightly favor a positive signal for at least one dose.

The trial is a well-designed Phase 2 dose-ranging study in moderate-to-severe UC, randomized, double-blind, placebo-controlled with three SAR443122 doses vs placebo. Primary endpoint is proportion achieving clinical remission by modified Mayo Score at Week 12—high-quality, validated composite of stool frequency, rectal bleeding, and endoscopy (≤1 no friability), standard for UC induction and regulatory-accepted. Patient population standard. Sanofi sponsor ensures strong operational execution; 'Active Not Recruiting' status post-enrollment despite 50-day primary completion delay suggests data nearing readout, low execution risk. No prior data for SAR443122 in UC implies novel mechanism, moderating expectations—historical Phase 2 UC dose-finding success ~40-45% for primary endpoint positivity (sig beat placebo on best dose). Maintenance and open-label rollover minimize attrition bias but irrelevant to primary. Low disclosure risk pre-topline. Strong design offset by efficacy uncertainty yields 45% intrinsic YES.

This Phase 2 dose-finding study for SAR443122 (Rilezolcitinib, a JAK inhibitor) in Ulcerative Colitis faces mixed signals. While the drug mechanism is validated (tofacitinib is approved for UC), Phase 2 dose-ranging studies often fail due to suboptimal exposure or safety signals. The primary endpoint (clinical remission at Week 12) is a high bar. The 'Active, not recruiting' status with a passed primary completion date suggests top-line results are imminent. Given the high failure rate in IBD drug development and the binary nature of the outcome, the probability is slightly less than a coin flip.

Phase 2 dose-finding study in moderate-to-severe UC with 4 parallel arms (3 doses vs placebo). Primary endpoint is clinical remission at Week 12 by modified Mayo Score, a well-validated regulatory endpoint. Sanofi has strong IBD experience. However, UC induction trials face high placebo response (~15-20% remission historically), and dose-ranging designs often show mixed results with only 1-2 active doses working. The drug (SAR443122, likely a small molecule immunomodulator) has no prior Phase 2 UC data disclosed, creating execution risk. Study completed primary completion 50 days ago but no results posted yet, suggesting potential data cleaning delays or strategic disclosure timing. The rollover design for non-responders indicates sponsor confidence but also acknowledges expected non-response rates. No safety signals disclosed yet. Overall, modest probability of clear positive readout given Phase 2 dose-finding attrition rates and competitive UC landscape.

SAR443122 (eclitasertib) is a peripherally restricted RIPK1 inhibitor. The baseline probability of success for a Phase 2 novel mechanism in UC is around 25-30%. However, the RIPK1 inhibitor class has an overwhelmingly negative clinical track record. GSK's RIPK1 inhibitor (GSK2982772) previously failed a Phase 2 trial in the exact same indication (ulcerative colitis) showing no significant difference versus placebo. Furthermore, SAR443122 already failed a Phase 2 trial in cutaneous lupus erythematosus (CLE). Its brain-penetrant sister molecule, oditrasertib (SAR443820), recently failed Phase 2 trials in both ALS and multiple sclerosis, leading Sanofi to terminate its development. Given the unbroken string of Phase 2 failures for RIPK1 inhibitors across multiple inflammatory and neurodegenerative indications—including a direct prior failure in active UC—the scientific rationale for this mechanism translating into human clinical efficacy is severely compromised. The primary endpoint evaluates clinical remission at Week 12, a high hurdle where placebo rates are typically 5-10%. It is highly improbable that SAR443122 will demonstrate statistically significant efficacy. The market pricing near 48% vastly overestimates the viability of this asset.

The trial is a Phase 2 dose-finding study evaluating the efficacy and safety of SAR443122 in participants with moderate to severe ulcerative colitis. The primary endpoint is clinical remission at Week 12 by modified Mayo Score. Given that the study is still active and not yet completed, there is uncertainty about the outcome. The sample size and specific doses being tested could impact the results. Additionally, the indication is challenging, and previous data on similar interventions have shown mixed results. Therefore, while there is potential for positive results, the likelihood is slightly below 50% based on the information provided.